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INTRODUCTION
Daikenchuto (DKT) is a traditional Japanese medicine (Kampo) and is a mixture of extract powders from dried Japanese pepper, processed ginger, ginseng radix and maltose powder, and has been used for the improvement of gastrointestinal motility, postoperative adhesion and paralytic ileus after abdominal surgery and its clinical efficacy is well established [1] [2] [3] [4] [5] . DKT may increase gastrointestinal motility by an up-regulation of the calcitonin gene-related peptide (CGRP) as well as acetylcholine release and plasma motilin 6-8).
CGRP is also the most powerful vasodilator and its vasodilatory effects following stimulated-release from the extrinsic sensory innervation is considered to serve as an important protective mechanism for maintaining mucosal integrity 9-12). Because blood flow has to meet the relatively high metabolic needs of the gastrointestinal tract as well as provide both valuable buffering and a pathway for removal of toxins that may have entered tissue 13). Therefore, maintaining or increasing blood flow is thought to be a central element in protecting the gastrointestinal tract 14) .
It has been demonstrated that calcitonin receptor-like receptor (CRLR), a receptor with seven transmembrane domains, matures to a Gs-protein-coupled CGRP receptor when co-expressed with single transmembrane domain receptor activity modifying protein 1 (RAMP1) 15, 16) . Therefore, to confirm the existence of a CGRP1 receptor, it is necessary to determine the existence of not only CRLR but also RAMP1.
In the present study, we investigated whether DKT has any effect on the colonic blood flow in rats and which component of DKT is responsible for DKT-induced hyperemia. We also investigated the mechanisms of DKT-induced hyperemia in colon by using blocker drugs pharmacologically and by using RT-PCR for presence of CGRP and its receptor components. 
MATERIALS AND METHODS

Ethical
Animal preparation and Measurement of colonic blood flow
Male Sprague-Dawley rats (Charles River Japan Inc., Tsukuba, Japan) weighing 250-315 g were fasted overnight but given free access to water. After urethane (900 mg/kg i.p.), α-chloralose (60 mg/kg i.p.) and butorphanol (2 mg/kg i.m.) anesthesia, a tracheal y-shaped cannula was inserted through the small section of the trachea to ventilate artificially (tidal volume; 8-10 mL/kg, respiratory rate; 60 breaths/min) in order to maintain a near-normal functional condition by a mechanical respirator (Respirator model SN 480-7, Shinano Co., Tokyo, Japan). The right femoral artery was cannulated and connected to a transducer (Colin BP508, Nihon Colin Co., Tokyo, Japan) to monitor systemic arterial blood pressure (AP) and heart rate (HR).
Electromyograms (EM) were recorded with bipolar intramuscular needle electrodes.
Body temperature was maintained at 37 ± 0.5 °C by a warming plate. After exposing the colon by a midline laparotomy, the cannula (25 G) was inserted via cecum into the proximal colon to facilitate injection of the drugs and to fix the proximal colon, the part of the distal colon (1 cm at length) was placed on wet absorbent cotton and filled with warmed physiological saline, then covered with saran wrap to keep warm, and prevent the tissue from becoming dehydrated.
Colonic blood flow was measured by non-contact laser tissue blood flowmetry (LaserMed, ALF21N, Advance Co., Tokyo, Japan) which is a well-characterized technique for the measurement of blood flow in the intestine. A fiberoptic probe was positioned against the surface (4 mm above) of the distal colon and secured inside the animal to prevent any movement of the tip of the probe during the course of the experiments. The penetration depth of the laser Doppler flowmetry system was 1 mm.
Blood flow, AP, HR, and EM were continuously monitored on PowerLab data-sampling unit (PowerLab8000, ADInstruments Co., Tokyo, Japan) and recorded on PC computer (Toshiba, Tokyo, Japan). Mean colonic vascular conductance (CVC) was calculated as the quotient of mean blood flow divided by mean AP and was expressed as mL/mmHg.
CVC was used as a reliable index of colonic blood flow 17-20).
Experimental protocol
After an equilibration period of 45 
RNA Extraction and RT-PCR
Total RNA was extracted from rat distal colon either vehicle for DKT or DKT administration (100 mg/kg) and homogenized colon tissues by Sepasol-RNA 1 (Nacalai Tesque Co., Kyoto, Japan) according to the manufacture's protocols. The quality and the quantity of the RNA were assessed at A 260/280, and all samples showed absorbency ratios ranging between 1.6 and 2. The polymerase chain reaction (PCR) utilized primers specific to CGRP, CRLR, RAMP1 and glyceraldehydes 3-phosphate dehydrogenase (GAPDH) genes which were designed based on published cDNA sequences (GenBank). Details of the primers used are summarized in Table 1 . The predicted sizes of the PCR products between two primers were 104 bp for CGRP, 504 bp for CRLR, 230 bp for RAMP1, and 249 bp for GAPDH, respectively, and which were used from previously reported 27, 28).
Commercially available one-step RT-PCR systems TaKaRa RNA PCR kit (AMV) Ver.3.0 (TakaRa-Biomedicals, Tokyo, Japan) was used, and all technical procedures The relative concentrations of CGRP, CRLR and RAMP1 mRNA were determined by densitometric analysis of the ethidium bromide-stained reaction products using Sigma Gel analysis system. The results were expressed as the ratio of the densitometric reading for CGRP, CRLR or RAMP1 to GAPDH mRNA from the same tissue.
Statistical analysis
All data are expressed as mean ± SEM. Comparisons between multiple groups were made by two-way analysis of variance (ANOVA) followed by Duncan's post hoc test.
Values of p<0.05 were considered significant.
RESULTS
Effects of DKT on CVC
In rats treated with vehicle for DKT, CVC did not change significantly during the 90 min period compared to the baseline, although there was a slight tendency for it to decrease ( Figure 1 ). Intracolonal administration of DKT (10, 100 and 300 mg/kg) increased basal CVC (0.10 ± 0.01) from the first 15-min observation period (0.14 ± 0.01, 0.17 ± 0.01, 0.17 ± 0.01 mL/mmHg, respectively) and with peak response at either 45 min (0.17 ± 0.02 mL/mmHg by 10 mg/kg), or 75 min and 60 min (0.23 ± 0.03 mL/mmHg and 0.21 ± 0.02 mL/mmHg by 100 mg/kg and 300 mg/kg, respectively), and returned to the 15-min level by 90 min after DKT administration (10, 100, 300 mg/kg, 0.13 ± 0.02, 0.16 ± 0.02, 0.16 ± 0.02 mL/mmHg, respectively) ( Figure 1 ). The maximum effect of DKT was observed in the 100 mg/kg group with peak response at 75 min which did not change significantly compared with the 300 mg/kg group (Figure 1 ).
The time course study of the CVC after DKT administration showed very similar patterns among the three different doses of DKT-treated groups at each time during the experimental period (Figure 1 ). The time course study of mean AP showed very similar patterns among the experimental groups. Mean AP was not affected by dose differences during the experimental period before and the 0-90 min period after either DKT, bp, and 249 bp, respectively (Figure 4a ). Sequence analysis of these RT-PCR products revealed that they were identical to each cDNA from the libraries.
Semi-quantification of the CGRP, CRLR and RAMP1 mRNA corrected by mRNA for GAPDH revealed significant increase of CGRP, CRLR and RAMP1 transcripts in the rat colon 45 min after DKT administration, compared to those transcripts in the control rat colon (Figure 4b ).
DISCUSSION
The present study first demonstrated that intracolonal administration of DKT increased CVC in rats. Moreover, this study showed that DKT did not affect mean AP, even when DKT was administered at the highest dose. This finding suggests that the increase in CVC by DKT results from a local vasodilator effect in intestinal blood vessels rather than being secondary to changes in systemic blood pressure. This observation also suggests that the hyperemic response to DKT mostly results from the upregulation of CGRP release and/or the upregulation of CGRP receptor. The results from the present study by RT-PCR revealed that DKT had an up-regulatory effect on CGRP and CGRP receptor. In addition, an increase in CVC was observed from immediately after DKT administration. This indicated that CGRP release might first be up-regulated by DKT, and then up-regulated RAMP1 might develop up-regulation of CGRP receptor followed by CGRP up-regulation. We believe that the present study have first discovered a part of the mechanism of the clinical effect of DKT. However, it is necessary for proving our proposal that further examination of CGRP and CGRP receptors protein level to rule out the possibility that the protein synthesis may not change even through the expression of mRNA increases.
DKT may be used as a CGRP up-regulator for intestine. Intestinal tissue CGRP is diminished in human and experimental Crohn's disease, and has been reported as a therapeutic and protective peptide 38-40). Therefore, we hypothesize that DKT has therapeutic effect on Crohn's disease via up-regulation of tissue CGRP and its receptor component. Next step of our investigations will be conducted focusing on the effect of DKT on Crohn's disease. 1, 4) . However, precise mechanism of the prevention from postoperative adhesion formation by DKT is still unknown.
In conclusion, the present study demonstrated that DKT produced an increase in CVC. Furthermore, the present results also suggest that DKT-induced hyperemia is mainly mediated by CGRP and its receptor components.
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